ArticlePharmaceuticals (Basel, Switzerland)2024

Jingzhi Guanxin Oral Liquids Attenuate Atherosclerotic Coronary Heart Disease via Modulating Lipid Metabolism and PPAR-Related Targets.

Xinning Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.